The serpin plasminogen activator inhibitor-1 (PAI-1) plays an important role in the regulation of the fibrinolytic activity in blood. In plasma, PAI-1 circulates mainly in the active conformation. However, PAI-1 spontaneously converts to a latent conformation. This conversion comprises drastic conformational changes in both the distal and the proximal hinge region of the reactive center loop. To study the functional and conformational rearrangements associated solely with the mobility of the proximal hinge, disulfide bonds were introduced to immobilize the distal hinge region. These mutants exhibited specific activities comparable with that of PAI-1-wt. However, the engineered disulfide bond had a major effect on the conformational and associated functional transitions. Strikingly, in contrast to PAI-1-wt, inactivation of these mutants yielded a virtually complete conversion to a substrate-like conformation. Comparison of the digestion pattern (with trypsin and elastase) of the mutants and PAI-1-wt revealed that the inactivated mutants have a conformation differing from that of latent and active PAI-1-wt. Unique trypsinsusceptible cleavage sites arose upon inactivation of these mutants. The localization of these exposed residues provides evidence that a displacement of ␣hF has occurred, indicating that the proximal hinge is partly inserted between s3A and s5A. In conclusion, immobilization of the distal hinge region in PAI-1 allowed the identification of an "intermediate" conformation characterized by a partial insertion of the proximal hinge region. We hypothesize that locking PAI-1 in this transition state between active and latent conformations is associated with a displacement of ␣hF, subsequently resulting in substrate behavior.
Plasminogen activator inhibitor-1 (PAI-1) 1 is the most important physiological inhibitor of tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) (1) . It plays an important role in the regulation of the fibrinolytic activity in human blood (2) . In addition to its role in fibrinolytic processes, PAI-1 has been demonstrated to be involved in a variety of other (patho)physiological processes.
PAI-1 is a member of the superfamily of the serpins. The three-dimensional structure of these glycoproteins consists of three ␤-sheets, nine ␣-helices, and a reactive center loop (RCL, P16 -P10Ј). Typically their active site comprises the P1-P1Ј (bait) residues, located on the RCL, thereby serving as a pseudo-substrate for the proteinase (3) . N-terminally, the RCL is connected via the so-called proximal hinge (P14 -P18) to ␤-strand 5 of the large central ␤-sheet A (s5A). C-terminally, the RCL is connected to s1C (i.e. the distal hinge region).
PAI-1 is unique among the serpins because of its functional and conformational flexibility. The active conformation of PAI-1 inhibits its target proteinases by the formation of a stable, inactive complex. After the formation of an initial, reversible Michaelis-like complex, the proteinase cleaves the active site of PAI-1 and forms a stable, covalent complex resulting in the inactivation of the proteinase (4, 5) .
PAI-1, which has a high second order rate constant for inhibition of t-PA of 2.0 ϫ 10 7 M Ϫ1 s Ϫ1 is distinguished from other serpins by the facile insertion of its RCL. This property is thought to be responsible for the spontaneous transformation of the unstable, active form of PAI-1 with a half-life (t1 ⁄2 ) of only 2.5 h at 37°C to a stable, inactive "latent" conformation (6) . In this latent conformation residues P15 to P4 of the RCL insert into the ␤-sheet A to form s4A, and residues P3 to P10Ј form an extended loop at the surface of the molecule (7) . Latent PAI-1 can be reconverted to the active form by denaturation and refolding (8) . Apart from their distinct functional properties, distinction between the active and latent conformations of PAI-1 can also be made based on differences in their proteolytic susceptibility (9 -11) . Depending on the mobility of the RCL, the presence of co-factors (e.g. heparin) and the proteinase used, PAI-1 can also be cleaved in a substrate-type reaction, resulting in an inactivated inhibitor (12) (13) (14) (15) . Some serpins require secondary interactions for efficient inhibition of the target proteinase. Additional interaction sites between PAI-1 and t-PA that stabilize the reversible, initially formed complex have been suggested (8, 16 -18) . The residues P4Ј, P5Ј, and P9Ј of PAI-1 were assumed to be important for this interaction (18, 19) .
As previously shown (20) , stabilizing mutations tend to be located in areas implicated in mobility of the serpin structure.
The latency transition requires an additional flexibility, in which strand 1C is peeled away from sheet C and passed through the gate region (7) . Overall, the stabilizing mutations can be grouped into five distinct subdomains of PAI-1, each of which has been associated with the latency transition: the vitronectin-binding domain, the helix F/loop subdomain, the helix C subdomain, the proximal hinge, and the sheet C/"back of the gate" region.
Based on these five subdomains, the following model for the consecutive steps involved in the latency transition of PAI-1 was proposed. First, the proximal hinge region of the RCL would insert up to the point where s1C starts to peel away. Judging from the structure of the ␣ 1 -antichymotrypsin ␦-form (21), about four residues of the P region can insert without movement of s1C. To allow further insertion of the P region, the helix F/loop subdomain will have to move aside with concomitant conformational changes within the vitronectin-binding domain and the C-helix, whereas s1C (PЈ region) passes through the gate region (22) . Finally, insertion of the remainder of the RCL takes place, resulting in the latent conformation. Based upon this proposed pathway, we hypothesized that immobilization of the distal hinge region (s1C) (a) might prolong the functional half-life of PAI-1, (b) might prevent typical latency transition (i.e. full RCL insertion), but (c) should not hamper the initial steps (i.e. partial insertion of the proximal hinge and displacement of ␣hF).
Characterization of mutants in which disulfide bonds were engineered to immobilize the distal hinge region revealed that the functional stability is indeed increased and that a conformational transition occurs in which PAI-1 is locked into a transition state between active and latent PAI-1. Importantly, this "intermediate" conformation is characterized by a partial insertion of the proximal hinge and a displacement of ␣hF, resulting in altered functional properties.
EXPERIMENTAL PROCEDURES

Materials
Oligonucleotides for mutagenesis and sequencing were purchased from Amersham Biosciences. Mutagenesis was performed using the QuikChange TM XL site-directed mutagenesis kit from Stratagene (La Jolla, CA). Pfu Turbo TM DNA polymerase was obtained from Stratagene. The PCRs were done with the Mastercycler gradient from Eppendorf (Hamburg, Germany). The expression vector pIGE20 was provided by Innogenetics (Ghent, Belgium), together with the bacterial strains Escherichia coli DH1 for cloning and MC1061 for expression as well as the pAcI plasmid encoding the thermolabile repressor. Plasmid DNA purification was performed using a Nucleobond TM purification kit (Macherey-Nagel, Germany). Agar and Luria Broth growth medium were purchased from Invitrogen. Dithiothreitol and the proteinase inhibitors leupeptin, phenylmethanesulfonyl fluoride, pepstatin, benzamidine HCl, and antipain were from Sigma. SP-Sepharose TM Fast Flow, Activated Thiol-Sepharose 4B and CNBr-activated Sepharose TM 4B were purchased from Amersham Biosciences. The thiol and sulfide quantitation kit was obtained from Molecular Probes (Leiden, The Netherlands). The chromogenic substrate S-2403 was obtained from Nodia/Chromogenix (Antwerp, Belgium). Tween 80 was purchased from Sigma. t-PA (predominantly single-chain) was a kind gift of Boehringer Ingelheim (Brussels, Belgium); u-PA (isolated from human urine and consisting of high and low molecular weight two-chain u-PA in a 75:25 ratio) was a kind gift from Bournonville Pharma (Braine l'Alleud, Belgium). Dr. Lijnen (University of Leuven, Leuven, Belgium) kindly provided plasmin. Trypsin and elastase were obtained from Sigma. Monoclonal antibodies raised against human PAI-1 were prepared as described previously (23, 24) . Recombinant human PAI-1 was produced in E. coli as described previously (10 
Methods
DNA Preparation
The mutants were constructed using the appropriate primers and pIGE20-PAI-1-wt 2 or pIGE20-PAI-1-variant as template. 50 ng of template and 20 pmol of each primer were used in the reaction. The PCR consisted of an initial denaturation step of 1 min at 94°C followed by 18 cycles of denaturation (50 s at 94°C), annealing (50 s at an appropriate temperature), and prolongation (10 min at 68°C). The reaction was ended by a final prolongation of 7 min at 68°C. Then 1 l of DpnI was added to digest (1 h at 37°C) the methylated parent vector (i.e. the template DNA).
Subsequently 100 ng of PCR product was transformed in E. coli DH1 cells followed by selection on agar plates containing tetracyclin (10 mg/liter). A single colony was grown overnight in 500 ml of LB containing tetracyclin (10 mg/liter), and the DNA was isolated using the Nucleobond TM AX 500 purification kit. Concentration and purity were measured by spectroscopic analysis. The presence of the mutation together with the absence of any unwanted mutation was verified by nucleotide sequencing.
Protein Preparation and Purification
Expression and purification was performed as described previously (10, 25) with minor modifications. Briefly, the recombinant plasmid, pIGE20-PAI-1-mutant, was transformed in E. coli MC1061 cells, together with the pAcI plasmid, containing the c1857 repressor gene, coding for a thermolabile repressor.
Isolated clones were grown overnight at 28°C in LB medium with tetracyclin (10 g/ml) and kanamycin (10 g/ml) on an orbital shaker at 300 rpm. Overnight cultures were diluted 1:100 and grown until the A 580 nm reached 0.2. Then PAI-1 expression was induced by increasing the temperature to 42°C. After 3 h, the cultures were centrifuged, the cell pellet was resuspended in 50 mM sodium acetate buffer, pH 5.5, containing 2 mM glutathione, and a mixture of proteinase inhibitors (leupeptin (final concentration, 2.5 g/ml), pepstatin A (0.9 g/ml), benzamidine HCl (203 g/ml), antipain (1.3 g/ml), phenylmethanesulfonyl fluoride (52 g/ml), and dithiothreitol (13 g/ml)). Subsequently the cells were disrupted in a standard French Pressure 20K (Aminco, Urbana, IL) cell. The cell lysate was cleared by centrifugation at 30,000 ϫ g for 20 min at 4°C. The obtained supernatant was immediately subjected to purification.
Purification was performed at 4°C using ion exchange chromatography and affinity chromatography. An SP-Sepharose TM Fast Flow column (30-ml beads) was equilibrated with a 0.15 M phosphate buffer containing 2 mM glutathione, pH 6.0 (buffer 1). The supernatant was diluted with a 0.15 M phosphate buffer containing NaCl and glutathione to obtain a final concentration of 0.2 M NaCl and 2 mM glutathione, pH 6.0, and loaded onto the column. After a washing step with buffer 1 containing 0.3 M NaCl, bound proteins were eluted using a 0.3-1.3 M NaCl gradient in buffer 1. PAI-1-containing fractions were pooled, dialyzed against buffer 1, and loaded onto a heparin-Sepharose column (10-ml beads) equilibrated with buffer 1. The column was washed with buffer 1, and bound PAI-1 was eluted using a 0.2-1.2 M NaCl gradient in buffer 1. Alternatively, for the purification of the mutants containing two cysteine residues, glutathione was omitted from all buffers resulting in a higher extent of disulfide bond formation.
PAI-1-containing fractions were subjected to SDS-PAGE for evaluation of their purity, pooled, and stored in aliquots at Ϫ20°C until use. The amount of PAI-1 protein in purified preparations was determined spectrophotometrically at 280 nm (absorbance coefficient A 1 cm 1% ϭ 10). Separation of oxidized and reduced forms was done on Activated Thiol-Sepharose TM 4B. The PAI-1-containing sample (1.5 ml, 750 g/ ml) was applied in binding buffer (140 mM NaCl, 2.7 mM KCl, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ) on a 6-ml column at a flow rate of 6 ml/h. After a washing step with binding buffer until the A reaches the initial value, bound protein (i.e. the reduced fractions) was eluted using phosphate-buffered saline with 15 mM dithiothreitol at a flow rate of 100 l/min. The nonbound fractions correspond to the oxidized form.
Protein Analysis
Quantification of the Disulfide Bridges-Quantification of the disulfide bridges was done with a thiol and sulfide quantitation kit (T6060) 2 The style for the names of PAI-1 derivatives is as follows: PAI-1-wt indicates PAI-1 wild type. Derivative names with mutations are abbreviated so that, for example, PAI-1-P270C indicates PAI-1 in which Pro 270 has been replaced by Cys.
(Molecular Probes). This kit provides a colorimetric assay for quantitating protein thiols, based upon a method reported by Singh et al. (26, 27) . PAI-1 samples were incubated with cystamine (final concentration, 2 mM). This molecule permits the detection of poorly accessible thiols on proteins or thiols that have high pK a values (26) . Cystamine, a disulfide, undergoes an exchange reaction with protein thiols, yielding 2-mercaptoethylamine (cysteamine), which then reduces a disulfideinhibited derivative of papain, stoichiometrically releasing the active enzyme. The amount of activated enzyme is then measured using the chromogenic substrate, N-benzoyl-L-arginine, p-nitroanilide. The calibration curves were constructed using L-cysteine. Alternatively, the percentage of oxidized forms was measured by SDS-PAGE because the oxidized form migrates slightly faster than the reduced form. PAI-1 samples were diluted with phosphate-buffered saline (140 mM NaCl, 2.7 mM KCl, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ) to a concentration between 0.1 and 0.2 mg/ml. After adding SDS (final concentration, 1%) and heating for 30 s at 100°C, they were analyzed by SDS-PAGE performed under both nonreducing and reducing conditions using 10 -15% gradient gels. The proteins were visualized by staining with Coomassie Brilliant Blue and quantified by densitometric scanning with the Imagemaster TM (Amersham Biosciences).
Determination of the Functional Distribution of PAI-1 and PAI-1
Variants-The PAI-1 samples were diluted with phosphate-buffered saline (140 mM NaCl, 2.7 mM KCl, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ) to a concentration between 0.1 and 0.3 mg/ml and incubated for 25 min at 37°C (or longer as mentioned in the individual experiments) with the serine proteinases (t-PA or u-PA) at a 2-fold molar excess. The reaction was terminated by adding SDS (final concentration, 1%) and heating for 30 s at 100°C. The reaction products were analyzed by SDS-PAGE performed under reducing conditions using 10 -15% gradient gels with the Phastsystem TM (Amersham Biosciences). The proteins were visualized by staining with Coomassie Brilliant Blue and quantified by densitometric scanning with the Imagemaster TM (Amersham Biosciences) as described previously (10) .
Determination of the Functional Stability-PAI-1 samples were diluted to a final concentration between 20 and 100 g/ml using the appropriate diluent (containing Na 2 HPO 4 ) to obtain a buffered solution with 45 mM phosphate, 70 mM NaCl, pH 7.4. The samples were incubated at 37°C, and aliquots were removed at various time points. The remaining inhibitory activity was evaluated by incubation with a 2-fold molar excess of t-PA for 25 min at 37°C and quantitative evaluation of formed complexes by SDS-PAGE (either silver-stained or Coomassiestained) and densitometric scanning. The amount of active PAI-1 at the various time points was expressed as a percentage of the initial amount of active PAI-1, and the decay was used for calculation of the half-life. Because of the slow reactivity between t-PA and PAI-1-P270C-A348C, u-PA instead of t-PA was used in the analysis of this mutant and the two respective single mutants.
Kinetic Analysis of the Inhibition of t-PA and u-PA by PAI-1 and PAI-1 Variants-The rate of inhibition of t-PA and u-PA by PAI-1 and PAI-1 variants was determined as described (28), with minor modifications. In brief, u-PA and t-PA were used at concentrations of 0.14 nM and PAI-1 and its variants at concentrations of 0.8 nM (pseudo first order conditions). Samples were taken at 0, 30, 60, 90, 120, 150, and 180 s, and the reactions were blocked by the addition of the monoclonal antibody MA-56A7C10 (for t-PA) or MA-8H9D4 (for u-PA) (28) at a 100-fold molar excess. Both antibodies inhibit PAI-1 activity very rapidly and completely, without interference on the t-PA or the u-PA activity assay used to quantify residual t-PA or u-PA activity (29, 30) . Second order rate constants were then determined as described (28) .
The rate of inhibition of the serine proteinases by slow reacting mutants (i.e. PAI-1-P270C-A348C and PAI-1-R271C-E350C) was determined by evaluation of complex formation using SDS-PAGE. Therefore these PAI-1 variants (150 g/ml) were incubated at 37°C with a 2-fold molar excess of the serine proteinase, and the formation of the covalent complex followed. Samples were taken at 0, 10, 30, 60, 120, 240, 420, 1200, and 2400 min. The reaction was terminated by adding SDS (final concentration, 1%) and heating for 30 s at 100°C. The rate of complex formation was determined using a one-phase exponential association, allowing calculation of the rate of inhibition (k ϭ ln2/(t1 ⁄2 ϫ concentration of serine proteinase)).
Trypsin and Elastase Digestion-PAI-1 samples were diluted with phosphate-buffered saline to a concentration between 20 and 50 g/ml. Trypsin or elastase were added at a proteinase:PAI-1 ratio of 1:10, and the mixtures were incubated at 37°C. At different time intervals between 0 and 240 min, a sample was removed, and the reaction was terminated by adding SDS (final concentration, 1%) and heating for 30 s at 100°C. The reaction products were analyzed by SDS-PAGE performed under reducing conditions using 10 -15% gradient gels and silver staining. The exact position of the observed cleavage sites was revealed through N-terminal amino acid analysis of isolated fragments (Eurosequence, Groningen, the Netherlands).
Heat Denaturation-Thermal denaturation profiles were determined as described (10, 28) . Briefly, PAI-1-containing samples were diluted to 20 g/ml in 20 mM sodium acetate, 1 M NaCl, 0.01% Tween 80, pH 5.5, and incubated for 2 h at a constant temperature, ranging from 0 to 90°C. Denaturated protein was removed by centrifugation (14,000 rpm), and the supernatant was stored on ice until analysis. Residual PAI-1 antigen was determined by enzyme-linked immunosorbent assay, using MA-31C9 and MA-55F4C12-HRP as capture and tagging antibodies, respectively. Residual PAI-1 antigen is expressed as a percentage of the initial value. The T m 50% value is the temperature at which 50% of the antigen is precipitated. Under these conditions active PAI-1 has been shown to have a T m 50% value around 50°C, and the substrate form has been shown to have a T m 50% value around 60°C. In contrast, the latent and cleaved form show a high resistance to heat denaturation (T m 50% Ͼ 90°C) (10) .
Statistical Analysis-The statistical significance of differences was evaluated using Student's t test or one-way analysis of variance; p values Ͼ 0.05 were considered not to be significant.
RESULTS
Selection of Amino Acids for
Mutagenesis-Taking into account (a) the possible effects of mutations on the activity and stability of PAI-1, (b) the orientations of the side chains in the three-dimensional structure, and (c) a maximum distance of 9 Å between two inserted thiol functions, the following disulfide mutants were designed ( 
Transition State in PAI-1
and PAI-1-V274C-I353C revealed a complete absence of activity and were not further characterized.
Quantification of the Disulfide Bridges-Purified disulfide PAI-1 variants contained varying amounts of reduced and oxidized forms. Further purification to achieve isolation of oxidized forms yielded fully oxidized preparations (Table I) . Using the colorimetric method, one could only deduce that over 86% occurred as an oxidized form consequent to limitations of the sensitivity of the method in combination with used protein concentrations. However, data from the SDS-PAGE analysis demonstrated that no detectable levels of reduced forms were present.
Determination of the Functional Distribution of PAI-1 and PAI-1 Variants-Incubation of PAI-1-wt with t-PA revealed the presence of the three typical functional forms (active, latent, and substrate) at relative ratios as expected (Table II , before inactivation). Also the single mutants revealed the presence of the three forms, even though for some at somewhat different ratios (Table II , before inactivation). Under these conditions (using longer incubation times where required to ensure a complete reaction) all three disulfide mutants also revealed the presence of the three typical functional forms. However, compared with PAI-1-wt the amount of cleavable material was significantly increased (26 -28% versus 16% for PAI-1-wt, p Ͻ 0.05).
As expected, the inactivation of PAI-1-wt at 37°C resulted in the formation of 85% latent PAI-1, whereas the amount of substrate remained unchanged. A similar shift in functional behavior was seen for the single mutants, except for PAI-1-R271C and PAI-1-P349C, which showed a 2-3-fold increased substrate behavior. In contrast, inactivation of the disulfide mutants at 37°C was mainly associated with a significant increase in substrate behavior (73-83% versus 15% for PAI-1-wt, p Ͻ 0.005; Table II, after inactivation).
It was also observed that cleavage of PAI-1-wt, PAI-1-P270C- Before inactivation PAI-1-wt 52 P349C, and PAI-1-R271C-E350C is completed after 25 min, compatible with the determined rates of cleavage (i.e. for PAI-1-wt and PAI-1-P270C-P349C less than 30 s and for PAI-1-R271C-E350C about 2-3 min). In contrast, the half-life for cleavage of PAI-1-P270C-A348C is about 3 h. Functional distribution data toward u-PA (data not shown) are in agreement with those obtained toward t-PA. Determination of the Functional Stability-Except for PAI-1-R271C, all single mutants exhibited a functional stability comparable with that of PAI-1-wt (Fig. 2) . In contrast all disulfide mutants had a significantly (p Ͻ 0.01) prolonged half-life, up to 10-fold increased versus PAI-1-wt.
Kinetic Analysis of the Inhibition of t-PA and u-PA by PAI-1 and PAI-1 Variants-Kinetic analysis showed no exceptional differences except for PAI-1-P270C-A348C and PAI-1-R271C-E350C (Table III) . PAI-1-P270C-A348C reacts more slowly both with t-PA and u-PA although to a different extent (i.e. 300,000-fold and 10-fold reduced, respectively; p Ͻ 0.001) (Table III). Strikingly PAI-1-R271C-E350C shows a two-phase association behavior. One fraction (i.e. 1 ⁄3 to 2 ⁄3 for the reaction toward t-PA and u-PA, respectively) of the active material exhibits a second order rate constant of inhibition comparable with that of PAI-1-wt (Table III) . The other fraction reacts much more slowly with a second order rate constant of inhibition 100,000 -350,000-fold reduced compared with that of PAI-1-wt (p Ͻ 0.001). No such two-phase kinetics was observed for the substrate reactions.
Trypsin and Elastase Digestion-Digestion patterns of the active conformation of the oxidized forms of the disulfide mutants were comparable with those observed with active PAI-1-wt (data not shown) (see Fig. 4A ). Strikingly, digestion of the inactivated forms of the disulfide mutants revealed a different digestion pattern, compared with that observed for inactivated PAI-1-wt. As expected, inactivated PAI-1-wt (latent conformation) is not cleaved by elastase (Figs. 3a and 4B ), whereas digestion of the inactivated mutants with elastase revealed cleavage in the RCL (Figs. 3b and 4C) , indicative for an accessibility of the RCL. Tryptic digests of inactivated (latent) PAI-1-wt (Figs. 3c and 4B ) yielded two fragments with a molecular mass of ϳ24 kDa corresponding to a cleavage at Lys 191 (9, 10) . In contrast, inactivated disulfide mutants yielded a different tryptic digestion pattern (Figs. 3d and 4C ) resulting in the generation of 16-and 28-kDa fragments corresponding with the N-and C-terminal parts of the protein, respectively. N-terminal amino acid sequencing of these fragments revealed that cleavage had occurred at positions Lys 145 or Lys 154 . Heat Denaturation-Heat denaturation profiles of PAI-1-wt and PAI-1 variants before inactivation revealed comparable T m 50% values, around 50°C (Table IV , before incubation) as observed previously for PAI-1-wt (10) . Inactivation of PAI-1-wt or of most of the single cysteine variants resulted in a significantly increased resistance to heat denaturation with T m values exceeding 80°C (Table IV, 
conformation (with a fully inserted RCL), as demonstrated previously for latent PAI-1-wt (10) . In contrast, the sensitivity to heat denaturation of PAI-1-R271C and the disulfide mutants remained virtually unchanged, indicative for the absence of loop-inserted forms and compatible with their functional behavior.
DISCUSSION
Based on a model concerning the consecutive steps involved in the latency transition of PAI-1, suggesting a side movement of s1C away from sheet C (7, 22, 31) , we hypothesized that immobilization of s1C could result in a stabilization of the active conformation but would not prevent movements in the proximal hinge. Immobilization of s1C resulted in a 4 -10-fold prolongation of the half-life but did not prevent inactivation. Further functional characterization of these inactivated forms toward their putative target proteinases t-PA and u-PA revealed that they did not behave as nonreactive, latent forms but rather as noninhibitory substrate-like forms. This observation indicates that in contrast to a latent conformation, the RCL of these inactivated mutants is still accessible, but in contrast to their active counterparts, the RCL has adopted a distinct conformation. Indeed, comparative proteolytic digestion experiments with trypsin revealed the presence of two previously nondescribed cleavage sites exclusively present in these inactivated disulfide-bonded mutants. Localization of these cleavage sites in the vicinity of ␣hF (i.e. located in the stretch connecting s3A and ␣hF) (Fig. 4C ) is strongly indicative for a different position of ␣hF in these inactivated variants, distinct from that in active and latent forms. Remarkably, a similar tryptic digestion pattern was observed with an inactivated substrate mutant, PAI-1-P13 (Val 3 Glu) (32), suggesting a direct link between this particular functional feature (i.e. substrate) and the conformational repositioning of ␣hF. Comparative heat denaturation experiments confirmed that in contrast to latent forms (characterized by the full insertion of the RCL and a subsequent increased resistance to heat denaturation), the overall conformation of these inactivated substratelike variants is comparable with that of active, RCL-exposed, forms (Fig. 4, B versus C and A) . We hypothesize that upon inactivation of these disulfide mutants, resulting in the generation of noninhibitory, substrate-like forms, the distal hinge region is not affected (i.e. adopts the same position as in the active forms), whereas the proximal hinge region (P18 -P14) becomes partly inserted (further insertion being prevented by the immobilization of s1C), resulting in a repositioning of ␣hF (Fig. 4C) . Thus, preinsertion of the proximal hinge of the RCL in combination with displacement of ␣hF provides an energetically unfavorable conformation, thereby rendering the serpin incapable of proceeding through the inhibitory pathway. It is well known that the interaction between a serpin and its target proteinases can either result in a cleaved serpin (substrate) or in the formation of a kinetically trapped covalent complex (inhibitor). One of the main factors governing the inhibitory versus substrate pathway is the kinetics of RCL insertion after formation of the acyl intermediate and ultimately leading to distortion of the catalytic triad of the proteinase. According to current theories (5, (33) (34) (35) , it is assumed that for inhibitory activity (a) full exposure of the RCL is required; (b) upon initial interaction with the target proteinase (noncovalent complex) no insertion has occurred yet; (c) partial insertion only starts after formation of the acyl intermediate; and (d) this insertion and movement of the proteinase results in a displacement of ␣hF, which acts as a spring, providing the energy required for proteinase crushing, leading to the ultimate stable covalent complex.
Our current observations demonstrate that not only the kinetics (36) but also the sequence of events is of the utmost importance in determining the substrate or inhibitory pathway. Indeed, it has been hypothesized that temporary displacement of ␣hF during serpin/proteinase interaction constitutes an essential coupling mechanism allowing a "successful" inhibitory process (34) . Our study demonstrates that even though insertion of RCL and displacement of ␣hF is required, it should not occur prior to interaction with the target proteinase but in a fine-tuned coordination with proteinase attack. These findings might suggest that although partial insertion (37) of the hinge region is a necessary step in the process of the formation of a stable serpin-enzyme complex (10, 31, 38, 39) , cleavage and subsequent (proteinase-induced) partial insertion should follow each other rapidly. Strikingly, this is in agreement with a previous suggestion (5) that the substrate behavior of antithrombin Hamilton may be caused by a premature partial preinsertion of s4A. These observations are also in agreement with the concept that in the inhibitory pathway cleavage of the P1-P1Ј bond precedes insertion of the hinge region (40, 41) .
Previous data have suggested that the mobility of strand 1C may be important to the function of serpins (42, 43) . Other experiments proved that in ␣1-AT, restricting the mobility of strand 1C did not significantly affect the inhibitory activity of the molecule (44) . Whereas the conformational changes in PAI-1 are influenced by the immobilization of s1C, our data confirm that uncoupling of strand 1C from ␤-sheet C is not necessary for the inhibitory activity of PAI-1. However, the much lower k i value observed for the reaction of t-PA with PAI-1-P270C-A348C suggests that the reaction is more efficient when the flexibility of the RCL is higher. Apparently, interaction with u-PA is less affected by these restrictions in flexibility. It should be noted that this effect on the k i is not merely caused by the mutation (Ala 3 Cys at position P2Ј) because the single mutation at position P2Ј had no effect on k i . For an as yet unknown reason PAI-1-R271C-E350C shows a two-phase association behavior both with t-PA and u-PA. This discrepancy points in the direction of two different inhibitory conformations, both being able to form stable complexes with the serine proteinases. The difference is most likely localized in the distal hinge region because this region is generally assumed to be important for the rate of formation of the initial, reversible, noncovalent complex.
In conclusion we have shown that immobilization of s1C does not affect the inhibitory properties in PAI-1 but does influence its functional/conformational changes. Inactivation of such variants leads to the formation of an intermediate conformation, in which the RCL is partially (pre)inserted and ␣hF is displaced, exerting substrate behavior. Detailed structural analysis of such variants will reveal the underlying molecular explanation for substrate behavior in PAI-1 and other serpins.
